Quince Therapeutics, Inc. (QNCX) Announces Results of 2026 Annual Meeting of Stockholders
South San Francisco, CA – June 11, 2026 – Quince Therapeutics, Inc. (NASDAQ: QNCX) has released the results of its 2026 Annual Meeting of Stockholders, held virtually on June 11, 2026. This report provides a comprehensive breakdown of the key proposals voted on by shareholders, including several actions that could have significant implications for the company’s capital structure and governance. The meeting was attended, in person virtually or by proxy, by holders of 6,255,339 shares of common stock, representing approximately 38.37% of the total outstanding shares eligible to be voted.
Key Highlights for Investors
- Reverse Stock Split Approved: Shareholders authorized a reverse stock split at a ratio ranging from 1-for-10 to 1-for-100, to be implemented at the Board’s discretion.
- Director Election: One Class I director was re-elected to the Board of Directors.
- Auditor Ratification: BDO USA, P.C. was ratified as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive Compensation: Shareholders approved, on an advisory basis, the compensation of the company’s named executive officers.
- Adjournment Flexibility: The Board was given the authority to adjourn or postpone the Annual Meeting to solicit additional proxies, if necessary.
Details of the Proposals and Results
Proposal 1: Election of Director
- Director Elected: June Bray was re-elected as a Class I director to serve until the 2029 annual meeting of stockholders or until her successor is duly elected and qualified.
- Votes For: 2,430,964
- Votes Withheld: 216,735
- Broker Non-Votes: 3,607,640
Proposal 2: Approval of Reverse Stock Split
- What Was Approved: Shareholders approved an amendment to Quince’s Amended and Restated Certificate of Incorporation to implement a reverse stock split of the company’s common stock. The approved ratio can be anywhere between 1-for-10 and 1-for-100, as determined by the Board at its discretion.
- Votes For: 4,715,574
- Votes Against: 1,517,896
- Abstentions: 21,866
Investor Note: A reverse stock split is a significant, potentially price-moving event. It reduces the number of shares outstanding and can have the effect of increasing the per-share price. The broad range (1-for-10 up to 1-for-100) gives the Board substantial flexibility. This move is often used to regain or maintain compliance with exchange listing requirements or to make shares more attractive to institutional investors. However, it does not affect the company’s market capitalization directly.
Proposal 3: Ratification of Auditors
- Auditor: BDO USA, P.C.
- Votes For: 6,080,608
- Votes Against: 111,522
- Abstentions: 63,207
This is a routine but important step for maintaining transparency and ensuring the integrity of the company’s financial reporting.
Proposal 4: Advisory Vote on Executive Compensation
- Votes For: 2,504,778
- Votes Against: 116,876
- Abstentions: 26,044
- Broker Non-Votes: 3,607,641
Shareholders approved the compensation of Quince’s named executive officers as disclosed in the proxy statement. While this advisory vote is non-binding, it signals shareholder support or concern regarding leadership pay.
Proposal 5: Adjournment of the Annual Meeting
- Votes For: 5,236,032
- Votes Against: 987,376
- Abstentions: 31,929
This proposal gives the Board flexibility to adjourn or postpone the meeting to solicit additional proxies if needed for the passage of any of the above proposals.
Other Corporate Information
- Company Name: Quince Therapeutics, Inc.
- Trading Symbol: QNCX
- Exchange: NASDAQ Stock Market
- State of Incorporation: Delaware
- Business Address: 611 Gateway Blvd., Suite 273, South San Francisco, CA 94080
- CEO & CMO: Dirk Thye
Potential Share Price Impact
- The approval of a reverse stock split is a key development that could have a material impact on the company’s share price and liquidity. Investors should monitor further communications from the company regarding the Board’s decision on the split ratio and timing.
- All other proposals were routine and received strong support from shareholders, indicating stability in governance and corporate direction.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. The information herein is derived from Quince Therapeutics’ official SEC 8-K filing dated June 11, 2026, and may be subject to change based on further company disclosures or market developments.
